TL;DR
This study identifies specific variants in the 3' untranslated region (3'UTR) of the IL18RAP gene as being protective against Amyotrophic Lateral Sclerosis (ALS). These variants appear to reduce neuroinflammation by dampening the IL-18-NF-κB signaling pathway in microglia, offering a potential new therapeutic avenue for ALS.
What Problem Does This Paper Address?
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease with a significant genetic component. While much research has focused on mutations in protein-coding genes, the vast non-coding regions of our genome remain largely unexplored for their role in disease. This paper addresses the challenge of identifying disease-associated variants in these non-coding regions, specifically the 3'UTRs of genes, and understanding their functional impact in ALS. The authors aim to uncover novel genetic risk factors and potential therapeutic targets by moving beyond the traditional focus on protein-coding genes.
Methods
The researchers employed a region-based burden analysis approach. This method aggregates rare genetic variants within specific genomic regions (like 3'UTRs) to assess their cumulative contribution to disease risk. They utilized whole-genome sequencing (WGS) data from a large cohort of ALS patients and controls. Key techniques included:
- Collapsed Region-Based Association Analysis: This statistical method bins rare variants within a defined region to test for an association with the disease.
- Optimized Sequence Kernel Association Test (SKAT-O): A standard statistical test for rare variant association analysis.
- RNA-binding protein pull-down assays and mass spectrometry: Used to identify proteins that interact with the IL18RAP 3'UTR.
- CRISPR-Cas9 genome editing: To create isogenic cell lines with specific IL18RAP 3'UTR variants.
- iPSC-derived microglia differentiation: To model the role of microglia in ALS.
- mRNA stability assays: To determine how variants affect the lifespan of IL18RAP mRNA.
- NF-κB reporter assays: To measure the activity of the NF-κB signaling pathway.
- RNA sequencing (MARS-seq): To analyze global changes in gene expression in microglia.
- Western blotting: To quantify protein levels.
Datasets
The study utilized the following datasets:
- Project MinE ALS sequencing consortium: This was the primary discovery cohort, comprising 3,955 ALS patients and 1,819 age- and sex-matched controls (totaling 5,774 whole genomes).
- Replication cohorts:
- European heritage ALS genomes from Project MinE datafreeze 2.
- New York Genome Center (NYGC) ALS Consortium cohort (2,184 ALS Spectrum MND and 263 non-neurological controls).
- NHLBI's Trans-Omics for Precision Medicine (TOPMed) (62,784 non-ALS genomes).
- gnomAD (5,537 non-ALS genomes).
- Human iPSC lines: Donated by ALS patients with C9orf72 repeat expansion.
- Mouse brain cells: Used for profiling cell-type specific expression of IL18RAP.
- Lymphoblastoid cell lines (LCLs): From healthy individuals and ALS patients.
- U2OS cells: Used for NF-κB reporter assays.
Key Insights and Ideas
- Non-coding regions hold crucial disease insights: The study strongly emphasizes that non-coding variants, particularly in 3'UTRs, can have significant impacts on disease risk, challenging the traditional focus on protein-coding genes.
- IL18RAP 3'UTR variants are protective: The identification of IL18RAP 3'UTR variants that are enriched in controls and associated with a reduced risk of ALS is a major finding. This suggests a protective role for these variants.
- Mechanism involves microglial inflammation: The research points to microglia, the immune cells of the brain, as key players. Variants in IL18RAP 3'UTR appear to dampen the inflammatory response mediated by microglia, which is implicated in ALS pathogenesis.
- IL-18/NF-κB pathway is central: The study elucidates a specific molecular pathway (IL-18 signaling leading to NF-κB activation) that is modulated by the protective IL18RAP variants.
- mRNA stability is a key regulatory mechanism: The variants appear to destabilize IL18RAP mRNA, leading to reduced protein expression and consequently, attenuated NF-κB signaling.
Key Results
- Significant association of IL18RAP 3'UTR variants with ALS: A five-fold reduced risk of developing ALS was observed in individuals with these variants.
- Replication in independent cohorts: The findings were consistently reproduced across multiple independent datasets, strengthening their validity.
- Functional impact on IL18RAP expression: Variants in the IL18RAP 3'UTR led to reduced IL18RAP mRNA and protein levels in both lymphoblastoid cells and iPSC-derived microglia.
- Attenuation of NF-κB signaling: The IL18RAP 3'UTR variants significantly reduced NF-κB activity in microglia and lymphoblastoid cells.
- Neuroprotective effect in vitro: Microglia harboring the variant IL18RAP 3'UTR showed a protective effect on motor neuron survival in co-culture experiments.
- Association with delayed disease onset and death: In patients with ALS who carried these variants, there was a trend towards older age of diagnosis and death, further supporting their protective role.
Limitations and Future Work
- Statistical power for non-coding regions: The authors acknowledge that the statistical power for detecting associations in non-coding regions might be lower compared to protein-coding regions, and larger cohorts may be needed to uncover additional variants.
- Focus on C9orf72 background: While the study used iPSCs with a C9orf72 repeat expansion, the authors suggest that exploring the role of IL18RAP 3'UTR variants in other ALS genetic backgrounds and other neurodegenerative diseases is warranted.
- Cell-type specificity: The current study focused on microglia. Future work should investigate the involvement of other cell types, such as motor neurons and astrocytes.
- Mechanism of dose sensitivity: The precise mechanism underlying IL18RAP dose sensitivity requires further investigation.
Summary updated